TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from NewAmsterdam Pharma Company ( (NAMS) ).
On August 18, 2025, NewAmsterdam Pharma announced that the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, both as a monotherapy and in combination with ezetimibe, for treating primary hypercholesterolemia and mixed dyslipidemia. This validation marks a significant step for NewAmsterdam, allowing the EMA to review pivotal Phase 3 trials, which demonstrated substantial LDL-C reductions. The company, in partnership with Menarini, aims to bring this novel treatment to Europe, potentially offering a new therapeutic option for patients not meeting LDL-C goals despite existing treatments.
The most recent analyst rating on (NAMS) stock is a Hold with a $23.60 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
NewAmsterdam Pharma’s overall stock score is driven by strong technical momentum and positive corporate events, particularly the promising Phase 3 trial results. However, the score is moderated by financial performance challenges, including lack of profitability and negative cash flows. The valuation remains a concern due to the negative P/E ratio, but the company’s growth potential in Alzheimer’s and cardiovascular treatments offers a compelling long-term opportunity.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol, particularly where existing therapies are insufficiently effective or well-tolerated.
Average Trading Volume: 862,394
Technical Sentiment Signal: Buy
Current Market Cap: $2.82B
See more insights into NAMS stock on TipRanks’ Stock Analysis page.